Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); Aduhelm (aducanumab-avwa) for alzheimer’s disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Lupus, Depression, CNS and neuromuscular disorders, Amyotrophic Lateral Sclerosis, and Alzheimer’s disease. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
225 Binney Street, Cambridge, Massachusetts, 02142
Website
www.biogen.com
Telephone
1 781 4642000
No of Employees
8,725
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIIB (NASD)
Revenue (2023)
$10.2B
-18.3%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-61.1%
(2023 vs 2022)
Market Cap*
$39.6B
Net Profit Margin (2022)
XYZ
-52.4%
(2023 vs 2022)
* As of and is in US$
Biogen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Aduhelm (aducanumab-avwa) - Alzheimer’s Disease | - |
| Avonex (interferon beta-1a) – Multiple Sclerosis | Alprolix |
| Fampyra (prolonged-release fampridine tablets) – Multiple Sclerosis | Avonex |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In February, the company and Sage Therapeutics Inc's Zuranolone has received U.S. Food and Drug Administration (FDA) approval for the treatment depressive disorder (MDD) and postpartum depression (PPD). |
| 2023 | Contracts/Agreements | In January, the company and Alcyone Therapeutics entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx System. |
| 2023 | Others | In January, the company and Eisai Co submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease to the European Medicines Agency. |
Competitor Comparison
| Key Parameters | Biogen Inc | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
| City | Cambridge | New Brunswick | Kenilworth | Paris | Basel |
| State/Province | Massachusetts | New Jersey | New Jersey | - | - |
| No. of Employees | 8,725 | 141,700 | 68,000 | 95,442 | 108,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stelios Papadopoulos, Ph.D. | Chairman | Executive Board | 2014 | 73 |
| Christopher Viehbacher | President; Director; Chief Executive Officer | Executive Board | 2022 | - |
| Michael McDonnell | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 59 |
| Robin C. Kramer | Chief Accounting Officer; Senior Vice President | Senior Management | 2020 | 57 |
| Susan H. Alexander | Chief Legal Officer; Secretary; Executive Vice President | Senior Management | 2011 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward